Intel Genx Technologies Corp. - Understand $igxt stock

$IGXT Market Cap: $41.92 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$1.051M

TTM

Gross Margin

-105.29%

TTM

Net Earnings

-$11.03M

TTM

Current Assets

$2.077M

Q1 2024

Current Liabilities

$16.52M

Q1 2024

Current Ratio

12.58%

Q1 2024

Total Assets

$6.548M

Q1 2024

Total Liabilities

$21.91M

Q1 2024

Book Value

-$15.37M

Q1 2024

Cash

$772.0K

Q1 2024

P/E

-3.801

Nov 11, 2024 EST

Free Cash Flow

-$7.221M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Revenue	$1.039M	$950.0K	$1.535M	$1.544M	$742.0K	$1.820M	$5.200M	$5.220M	$5.100M	$1.660M	$950.0K	$1.200M	$440.0K	$1.340M	$1.280M	$980.0K	$860.0K	$270.0K	$20.00K
YoY Change	9.37%	-38.11%	-0.58%	108.09%	-59.23%	-65.0%	-0.38%	2.35%	207.23%	74.74%	-20.83%	172.73%	-67.16%	4.69%	30.61%	13.95%	218.52%	1250.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Revenue	$1.039M	$950.0K	$1.535M	$1.544M	$742.0K	$1.820M	$5.200M	$5.220M	$5.100M	$1.660M	$950.0K	$1.200M	$440.0K	$1.340M	$1.280M	$980.0K	$860.0K	$270.0K	$20.00K
Cost Of Revenue	$1.733M	$1.858M	$2.260M			$0.00	$370.0K	$320.0K	$430.0K
Gross Profit	-$694.0K	-$908.0K	-$720.0K			$1.820M	$4.820M	$4.900M	$4.660M
Gross Profit Margin	-66.79%	-95.58%	-46.91%			100.0%	92.69%	93.87%	91.37%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Selling, General & Admin	$4.757M	$4.697M	$3.750M	$4.437M	$5.800M	$5.000M	$3.970M	$3.610M	$2.070M	$2.290M	$1.950M	$1.690M	$1.510M	$2.730M	$1.380M	$1.460M	$920.0K	$490.0K	$70.00K
YoY Change	1.28%	25.25%	-15.48%	-23.5%	16.0%	25.94%	9.97%	74.4%	-9.61%	17.44%	15.38%	11.92%	-44.69%	97.83%	-5.48%	58.7%	87.76%	600.0%
% of Gross Profit						274.73%	82.37%	73.67%	44.42%
Research & Development	$3.274M	$3.031M	$2.720M	$2.637M	$3.774M	$5.100M	$2.620M	$1.770M	$1.030M	$1.080M	$560.0K	$1.720M	$1.340M	$1.570M	$1.240M	$1.780M	$600.0K	$470.0K	$50.00K
YoY Change	8.02%	11.43%	3.15%	-30.13%	-26.0%	94.66%	48.02%	71.84%	-4.63%	92.86%	-67.44%	28.36%	-14.65%	26.61%	-30.34%	196.67%	27.66%	840.0%
% of Gross Profit						280.22%	54.36%	36.12%	22.1%
Depreciation & Amortization	$766.0K	$777.0K	$791.0K	$734.0K	$718.0K	$720.0K	$740.0K	$510.0K	$170.0K	$70.00K	$70.00K	$50.00K	$40.00K	$40.00K	$40.00K	$50.00K	$40.00K	$30.00K	$20.00K
YoY Change	-1.42%	-1.77%	7.77%	2.23%	-0.28%	-2.7%	45.1%	200.0%	142.86%	0.0%	40.0%	25.0%	0.0%	0.0%	-20.0%	25.0%	33.33%	50.0%
% of Gross Profit						39.56%	15.35%	10.41%	3.65%
Operating Expenses	$10.53M	$10.36M	$7.260M	$7.808M	$10.29M	$10.82M	$7.320M	$5.880M	$3.280M	$3.440M	$2.590M	$3.460M	$2.880M	$4.340M	$2.660M	$3.290M	$1.570M	$1.000M	$150.0K
YoY Change	1.61%	42.74%	-7.02%	-24.14%	-4.88%	47.81%	24.49%	79.27%	-4.65%	32.82%	-25.14%	20.14%	-33.64%	63.16%	-19.15%	109.55%	57.0%	566.67%
Operating Profit	-$9.491M	-$9.413M	-$7.980M	-$6.264M	-$9.550M	-$9.000M	-$2.500M	-$980.0K	$1.380M
YoY Change	0.83%	17.96%	27.39%	-34.41%	6.11%	260.0%	155.1%	-171.01%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Interest Expense	$1.625M	$1.281M	-$1.340M	$1.202M	$1.207M	-$1.110M	-$560.0K	-$200.0K	-$100.0K	$30.00K	$0.00	$10.00K	-$10.00K	-$90.00K	-$690.0K	-$640.0K	-$460.0K	-$50.00K	-$10.00K
YoY Change	26.85%	-195.6%	-211.48%	-0.41%	-208.74%	98.21%	180.0%	100.0%	-433.33%		-100.0%	-200.0%	-88.89%	-86.96%	7.81%	39.13%	820.0%	400.0%
% of Operating Profit									-7.25%
Other Income/Expense, Net	-$436.0K	-$1.277M	-$1.336M	-$780.0K	-$1.110M
YoY Change	-65.86%	-4.42%	71.28%	-29.73%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Pretax Income	-$9.927M	-$10.69M	-$9.318M	-$7.044M	-$10.66M	-$10.11M	-$3.050M	-$1.180M	$1.290M	-$1.750M	-$1.640M	-$2.250M	-$2.450M	-$3.100M	-$2.070M	-$2.960M	-$1.170M	-$780.0K	-$140.0K
YoY Change	-7.14%	14.72%	32.28%	-33.92%	5.44%	231.48%	158.47%	-191.47%	-173.71%	6.71%	-27.11%	-8.16%	-20.97%	49.76%	-30.07%	152.99%	50.0%	457.14%
Income Tax	$0.00	$0.00	-$10.00K	$0.00	$0.00	$0.00		$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	-$130.0K	-$150.0K	-$60.00K	$0.00	-$10.00K
% Of Pretax Income									0.0%
Net Earnings	-$9.927M	-$10.69M	-$9.312M	-$7.044M	-$10.66M	-$10.11M	-$3.050M	-$1.180M	$1.290M	-$1.750M	-$1.640M	-$2.250M	-$2.450M	-$3.100M	-$1.940M	-$2.810M	-$1.100M	-$780.0K	-$130.0K
YoY Change	-7.14%	14.8%	32.2%	-33.92%	5.46%	231.41%	158.47%	-191.47%	-173.71%	6.71%	-27.11%	-8.16%	-20.97%	59.79%	-30.96%	155.45%	41.03%	500.0%
Net Earnings / Revenue	-955.44%	-1125.26%	-606.64%	-456.22%	-1436.66%	-555.38%	-58.65%	-22.61%	25.29%	-105.42%	-172.63%	-187.5%	-556.82%	-231.34%	-151.56%	-286.73%	-127.91%	-288.89%	-650.0%
Basic Earnings Per Share	-$0.06	-$0.07	-$0.07
Diluted Earnings Per Share	-$0.06	-$0.07	-$67.96K	-$64.92K	-$114.0K	-$136.4K	-$46.11K	-$18.45K	$18.20K	-$27.70K	-$30.36K	-$45.33K	-$56.01K	-$87.74K	-$79.09K	-$142.9K	-$68.58K	-$54.39K	-$11.83K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Cash & Short-Term Investments	$2.282M	$2.527M	$9.950M	$2.240M	$1.910M	$11.00M	$4.900M	$4.500M	$2.870M	$4.400M	$5.010M	$2.060M	$3.510M	$1.140M	$1.520M	$560.0K	$330.0K	$230.0K	$10.00K
YoY Change	-9.7%	-74.6%	344.2%	17.28%	-82.64%	124.49%	8.89%	56.79%	-34.77%	-12.18%	143.2%	-41.31%	207.89%	-25.0%	171.43%	69.7%	43.48%	2200.0%
Cash & Equivalents			$3.950M	$1.210M	$1.330M	$6.820M	$1.590M	$610.0K	$2.870M	$4.400M	$5.010M	$2.060M	$3.510M	$1.140M	$1.520M	$560.0K	$330.0K	$230.0K	$10.00K
Short-Term Investments	$0.00	$1.317M	$6.000M	$1.040M	$580.0K	$4.180M	$3.310M	$3.880M
Other Short-Term Assets	$298.0K	$331.0K	$320.0K	$570.0K	$170.0K	$460.0K	$200.0K	$570.0K	$70.00K	$100.0K	$130.0K	$100.0K	$70.00K	$50.00K	$50.00K	$330.0K	$20.00K	$70.00K	$0.00
YoY Change	-9.97%	3.44%	-43.86%	235.29%	-63.04%	130.0%	-64.91%	714.29%	-30.0%	-23.08%	30.0%	42.86%	40.0%	0.0%	-84.85%	1550.0%	-71.43%
Inventory	$71.00K	$62.00K	$60.00K	$240.0K	$380.0K	$380.0K
Prepaid Expenses
Receivables	$622.0K	$709.0K	$680.0K	$610.0K	$380.0K	$820.0K	$620.0K	$1.040M	$1.140M	$650.0K	$140.0K	$1.280M	$260.0K	$280.0K	$620.0K	$320.0K	$430.0K	$140.0K	$10.00K
Other Receivables	$168.0K	$159.0K	$440.0K	$640.0K	$380.0K	$410.0K	$320.0K	$250.0K	$100.0K	$110.0K	$270.0K	$220.0K	$460.0K	$200.0K	$510.0K	$270.0K	$250.0K	$50.00K	$80.00K
Total Short-Term Assets	$3.441M	$3.788M	$11.44M	$4.310M	$3.220M	$13.06M	$6.040M	$6.350M	$4.170M	$5.260M	$5.550M	$3.660M	$4.300M	$1.670M	$2.700M	$1.460M	$1.040M	$490.0K	$100.0K
YoY Change	-9.16%	-66.89%	165.43%	33.85%	-75.34%	116.23%	-4.88%	52.28%	-20.72%	-5.23%	51.64%	-14.88%	157.49%	-38.15%	84.93%	40.38%	112.24%	390.0%
Property, Plant & Equipment	$4.591M	$5.157M	$6.220M	$6.560M	$7.050M	$6.250M	$6.350M	$5.730M	$4.240M	$980.0K	$590.0K	$390.0K	$150.0K	$160.0K	$160.0K	$160.0K	$240.0K	$160.0K	$100.0K
YoY Change	-10.98%	-17.09%	-5.18%	-6.95%	12.8%	-1.57%	10.82%	35.14%	332.65%	66.1%	51.28%	160.0%	-6.25%	0.0%	0.0%	-33.33%	50.0%	60.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$250.0K	$245.0K	$250.0K	$250.0K	$750.0K	$710.0K	$760.0K	$710.0K	$510.0K
YoY Change	2.04%	-2.0%	0.0%	-66.67%	5.63%	-6.58%	7.04%	39.22%
Total Long-Term Assets	$4.841M	$5.402M	$6.470M	$6.810M	$7.800M	$6.960M	$7.110M	$6.440M	$4.750M	$1.020M	$670.0K	$500.0K	$270.0K	$160.0K	$160.0K	$160.0K	$230.0K	$160.0K	$100.0K
YoY Change	-10.39%	-16.51%	-4.99%	-12.69%	12.07%	-2.11%	10.4%	35.58%	365.69%	52.24%	34.0%	85.19%	68.75%	0.0%	0.0%	-30.43%	43.75%	60.0%
Total Assets	$8.282M	$9.190M	$17.91M	$11.12M	$11.02M	$20.02M	$13.15M	$12.79M	$8.920M	$6.280M	$6.220M	$4.160M	$4.570M	$1.830M	$2.860M	$1.620M	$1.270M	$650.0K	$200.0K
YoY Change
Accounts Payable	$2.661M	$2.102M	$2.300M	$1.990M	$1.940M	$2.030M	$1.310M	$900.0K	$1.600M	$470.0K	$590.0K	$1.060M	$670.0K	$350.0K	$690.0K	$530.0K	$260.0K	$130.0K	$70.00K
YoY Change	26.59%	-8.61%	15.58%	2.58%	-4.43%	54.96%	45.56%	-43.75%	240.43%	-20.34%	-44.34%	58.21%	91.43%	-49.28%	30.19%	103.85%	100.0%	85.71%
Accrued Expenses	$1.497M	$236.0K	$250.0K	$140.0K	$140.0K									$0.00	$10.00K
YoY Change	534.32%	-5.6%	78.57%	0.0%										-100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$3.057M	$0.00	$0.00	$1.490M	$5.640M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$720.0K	$0.00	$0.00	$0.00
YoY Change			-100.0%	-73.58%											-100.0%
Long-Term Debt Due	$90.00K	$36.00K	$4.280M	$590.0K	$730.0K	$690.0K	$770.0K	$700.0K	$180.0K								$0.00	$20.00K	$10.00K
YoY Change	150.0%	-99.16%	625.42%	-19.18%	5.8%	-10.39%	10.0%	288.89%									-100.0%	100.0%
Total Short-Term Liabilities	$8.423M	$2.374M	$7.020M	$4.370M	$8.450M	$2.720M	$2.080M	$5.240M	$1.780M	$1.710M	$900.0K	$1.370M	$670.0K	$350.0K	$700.0K	$1.370M	$260.0K	$150.0K	$80.00K
YoY Change	254.8%	-66.18%	60.64%	-48.28%	210.66%	30.77%	-60.31%	194.38%	4.09%	90.0%	-34.31%	104.48%	91.43%	-50.0%	-48.91%	426.92%	73.33%	87.5%
Long-Term Debt	$11.88M	$9.814M	$6.290M	$7.220M	$1.730M	$7.260M	$7.190M	$2.570M	$1.550M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$80.00K	$520.0K	$170.0K	$150.0K
YoY Change	21.01%	56.03%	-12.88%	317.34%	-76.17%	0.97%	179.77%	65.81%							-100.0%	-84.62%	205.88%	13.33%
Other Long-Term Liabilities	$230.0K	$425.0K	$640.0K	$480.0K	$560.0K	$50.00K	$50.00K	$50.00K	$30.00K	$0.00	$310.0K	$620.0K	$0.00
YoY Change	-45.88%	-33.59%	33.33%	-14.29%	1020.0%	0.0%	0.0%	66.67%		-100.0%	-50.0%
Total Long-Term Liabilities	$12.11M	$10.24M	$6.930M	$7.700M	$2.290M	$7.310M	$7.240M	$2.620M	$1.580M	$0.00	$310.0K	$620.0K	$0.00	$0.00	$0.00	$80.00K	$520.0K	$170.0K	$150.0K
YoY Change	18.23%	47.75%	-10.0%	236.24%	-68.67%	0.97%	176.34%	65.82%		-100.0%	-50.0%				-100.0%	-84.62%	205.88%	13.33%
Total Liabilities	$20.53M	$12.61M	$14.03M	$12.07M	$10.73M	$10.03M	$9.320M	$7.850M	$3.350M	$1.710M	$1.210M	$1.980M	$670.0K	$350.0K	$700.0K	$1.450M	$1.060M	$320.0K	$230.0K
YoY Change	62.76%	-10.1%	16.24%	12.49%	6.98%	7.62%	18.73%	134.33%	95.91%	41.32%	-38.89%	195.52%	91.43%	-50.0%	-51.72%	36.79%	231.25%	39.13%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021
Basic Shares Outstanding	174.7M shares	164.7M shares	137.0M shares
Diluted Shares Outstanding	174.7M shares	164.7M shares	137.0M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $41.92 Million

About IntelGenx Technologies Corp.

IntelGenx Technologies Corp. is a drug delivery company, which focuses on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilm technology platform. The company is headquartered in Saint-Laurent, Quebec. The firm provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allows for pharmaceutical products that address unmet medical needs. The company provides comprehensive pharmaceuticals services to pharmaceutical partners, including research and development (R&D), analytical method development, clinical monitoring, IP and regulatory services. Its manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. Its product portfolio includes Migraine (Rizatriptan), Erectile Dysfunction (Tadalafil), Schizophrenia (Lozapine), Neurodegenerative, Opioid Dependence (Buprenorphine / Naloxone) and others.

Industry: Pharmaceutical Preparations Peers: Allied Corp.